Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation)usually mild to moderate and often diminishing over time Injection site reactions Headache Fatigue More serious but rare adverse effects have been identified, including: Pancreatitis patients should seek urgent medical advice for severe, persistent abdominal pain (with or without vomiting) Gallbladder disease symptoms include upper right abdominal pain and jaundice Diabetic retinopathy complications particularly with rapid HbA1c reduction in patients with pre-existing retinopathy Dehydration and acute kidney injury from persistent gastrointestinal symptoms When combined with sulfonylureas or insulin, GLP-1 receptor agonists increase the risk of hypoglycaemia
Understanding these changes can help patients prepare for the transition and recognise what is normal during this period
Regular consultation with healthcare professionals is essential to determine the optimal dosage, frequency, and duration of B12 IM injections based on individual needs and health status
While most studies focused specifically on cirrhosis, a small subset addressed chronic liver disease without cirrhosis, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and chronic hepatitis